Vernalis plc (LON:VER) insider Carol Ferguson purchased 28,000 shares of the stock in a transaction dated Friday, September 30th. The shares were bought at an average price of GBX 41 ($0.54) per share, for a total transaction of £11,480 ($14,984.99).
Shares of Vernalis plc (LON:VER) traded up 3.70% during midday trading on Friday, reaching GBX 42.00. 256,354 shares of the company were exchanged. Vernalis plc has a 52-week low of GBX 31.00 and a 52-week high of GBX 79.00. The company’s market capitalization is GBX 186.95 million. The stock has a 50-day moving average price of GBX 43.70 and a 200 day moving average price of GBX 45.74.
Several research firms have recently commented on VER. Stifel Nicolaus restated a “buy” rating and set a GBX 99 ($1.29) price target on shares of Vernalis plc in a report on Thursday. Panmure Gordon restated a “buy” rating and set a GBX 76 ($0.99) price target on shares of Vernalis plc in a report on Friday, July 8th. Shore Capital restated a “house stock” rating on shares of Vernalis plc in a report on Friday, July 8th. Canaccord Genuity restated a “buy” rating and set a GBX 84 ($1.10) price target on shares of Vernalis plc in a report on Tuesday, September 6th. Finally, N+1 Singer restated a “hold” rating and set a GBX 46 ($0.60) price target on shares of Vernalis plc in a report on Thursday. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. Vernalis plc currently has an average rating of “Buy” and an average target price of GBX 73 ($0.95).
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with MarketBeat.com's FREE daily email newsletter.